Johnson & Johnson Income After Taxes 2010-2024 | JNJ
Johnson & Johnson annual/quarterly income after taxes history and growth rate from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
- Johnson & Johnson income after taxes for the quarter ending September 30, 2024 was $2.694B, a 37.48% decline year-over-year.
- Johnson & Johnson income after taxes for the twelve months ending September 30, 2024 was $14.767B, a 30.79% increase year-over-year.
- Johnson & Johnson annual income after taxes for 2023 was $13.326B, a 18.59% decline from 2022.
- Johnson & Johnson annual income after taxes for 2022 was $16.37B, a 8.04% decline from 2021.
- Johnson & Johnson annual income after taxes for 2021 was $17.801B, a 20.98% increase from 2020.
Johnson & Johnson Annual Income After Taxes
(Millions of US $) |
| 2023 |
$13,326 |
| 2022 |
$16,370 |
| 2021 |
$17,801 |
| 2020 |
$14,714 |
| 2019 |
$15,119 |
| 2018 |
$15,297 |
| 2017 |
$1,300 |
| 2016 |
$16,540 |
| 2015 |
$15,409 |
| 2014 |
$16,323 |
| 2013 |
$13,831 |
| 2012 |
$10,514 |
| 2011 |
$9,672 |
| 2010 |
$13,334 |
| 2009 |
$12,266 |
Johnson & Johnson Quarterly Income After Taxes
(Millions of US $) |
| 2024-09-30 |
$2,694 |
| 2024-06-30 |
$4,686 |
| 2024-03-31 |
$3,255 |
| 2023-12-31 |
$4,132 |
| 2023-09-30 |
$4,309 |
| 2023-06-30 |
$5,376 |
| 2023-03-31 |
$-491 |
| 2022-12-31 |
$2,097 |
| 2022-09-30 |
$4,310 |
| 2022-06-30 |
$4,814 |
| 2022-03-31 |
$5,149 |
| 2021-12-31 |
$1,659 |
| 2021-09-30 |
$3,667 |
| 2021-06-30 |
$6,278 |
| 2021-03-31 |
$6,197 |
| 2020-12-31 |
$1,738 |
| 2020-09-30 |
$3,554 |
| 2020-06-30 |
$3,626 |
| 2020-03-31 |
$5,796 |
| 2019-12-31 |
$4,010 |
| 2019-09-30 |
$1,753 |
| 2019-06-30 |
$5,607 |
| 2019-03-31 |
$3,749 |
| 2018-12-31 |
$3,042 |
| 2018-09-30 |
$3,934 |
| 2018-06-30 |
$3,954 |
| 2018-03-31 |
$4,367 |
| 2017-12-31 |
$-10,713 |
| 2017-09-30 |
$3,764 |
| 2017-06-30 |
$3,827 |
| 2017-03-31 |
$4,422 |
| 2016-12-31 |
$3,814 |
| 2016-09-30 |
$4,272 |
| 2016-06-30 |
$3,997 |
| 2016-03-31 |
$4,457 |
| 2015-12-31 |
$3,215 |
| 2015-09-30 |
$3,358 |
| 2015-06-30 |
$4,516 |
| 2015-03-31 |
$4,320 |
| 2014-12-31 |
$2,521 |
| 2014-09-30 |
$4,749 |
| 2014-06-30 |
$4,326 |
| 2014-03-31 |
$4,727 |
| 2013-12-31 |
$3,519 |
| 2013-09-30 |
$2,982 |
| 2013-06-30 |
$3,833 |
| 2013-03-31 |
$3,497 |
| 2012-12-31 |
$2,567 |
| 2012-09-30 |
$2,629 |
| 2012-06-30 |
$1,408 |
| 2012-03-31 |
$3,910 |
| 2011-12-31 |
$218 |
| 2011-09-30 |
$3,202 |
| 2011-06-30 |
$2,776 |
| 2011-03-31 |
$3,476 |
| 2010-12-31 |
$1,942 |
| 2010-09-30 |
$3,417 |
| 2010-06-30 |
$3,449 |
| 2010-03-31 |
$4,526 |
| 2009-12-31 |
$2,206 |
| 2009-09-30 |
$3,345 |
| 2009-06-30 |
$3,208 |
| 2009-03-31 |
$3,507 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$373.591B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
